Intharit Ninnart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Intharit Ninnart has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Arunporn Itharat
Department of Applied Thai Traditional Medicine, Faculty of Medicine, Thammasat University, Klongluang, Pathumthani 12120, Thailand
2 shared publications - Kalyarut Phumlek
Department of Pharmaceutical Chemistry and Pharmacognosy, Faculty of Pharmaceutical Sciences and Center of Excellence for Innovation in Chemistry, Naresuan University, Phitsanulok 65000, Thailand
2 shared publications - Theeraphong Ninlaor
Department of Applied Thai Traditional Medicine and Center of Excellence in Applied Thai Traditional Medicine Research (CEATMR), Faculty of Medicine, Thammasat University (Rangsit campus), Klong Luang, Pathum Thani, 12120, Thailand
2 shared publications - Boonchana Pongcharoen
Department of Orthopedic Surgery, Faculty of Medicine, Thammasat University (Rangsit campus), Khlong Luang, Pathum Thani, 12120, Thailand
1 shared publication - Chatchai Mingmalairak
Department of Surgery, Faculty of Medicine, Thammasat University, Pathumthani, Thailand
1 shared publication Loebenberg Raimar
1 shared publication
Latest Publications
- Open Access
- 14 February 2026
- Published by Elsevier in Journal of Traditional and Complementary Medicine
- Vol. 16 (4) , 458-466
A double-blinded randomized clinical trial: Topical Sahasthara extract versus diclofenac for treating primary knee osteoarthritis using microemulsions as a topical delivery system
- 14 February 2026
- Published by Elsevier in Journal of Traditional and Complementary Medicine
- Vol. 16 (4) , 458-466
Open AccessA double-blinded randomized clinical trial: Topical Sahasthara extract versus diclofenac for treating primary knee osteoarthritis using microemulsions as a topical delivery system
- Open Access
- 1 September 2025
- Published by Garval Editorial Ltda. in Journal of Pharmacy & Pharmacognosy Research
- Vol. 13 (5) , 1451-1473
Exploring traditional uses and biological activities related to liver cancer of Saban remedy extracts for potential liver cancer treatment
Context: Saban remedy is used at Khampramong Temple to relieve adverse effects in liver cancer patients. Aims: To analyze the taste and biological activities of Saban remedy and Cassia garrettiana as a principal component species in liver cancer treatment supported in vitro and in vivo. Methods: Saban remedy and its ingredient extracts were tested for cytotoxic activity against hepatocellular carcinoma (HepG2, KKU-M156), cholangiocarcinoma cells, and normal human lung fibroblast cells (MRC-5) using the sulforhodamine B assay. Anti-inflammatory effects were evaluated through inhibition of inflammatory cytokine production (RAW 264.7 cell line), and mutagenicity and anti-mutagenicity were assessed using the Salmonella typhimurium strain TA98 and TA100 mutation assay. Both Saban remedy extracts and ethanolic C. garrettiana extract were tested in vivo for anti-hepatocarcinogenesis during the initiation stage in male Wistar rats. Results: Saban remedy, traditionally used as a purgative, exhibited bitter and bitter-nauseating flavors. The remedy demonstrated in vitro cytotoxic activity and in vivo reduction of GST-P foci in liver tissue, indicating protective and therapeutic potential against liver cancer. Saban remedy ethanolic extracts showed significant anti-inflammatory effects through nitric oxide inhibition. Notably, the aqueous extract of Saban remedy effectively reduced GST-P foci, a preneoplastic liver lesion, though it exhibited fewer biological activities compared to the ethanolic extract. This aligns with Khampramong Temple’s clinical use of the aqueous solution in cancer patients. Conclusions: The taste and biological properties of Saban remedy are correlated, supporting its use in treating liver cancer through various bioactivities.
- 1 September 2025
- Published by Garval Editorial Ltda. in Journal of Pharmacy & Pharmacognosy Research
- Vol. 13 (5) , 1451-1473
Open AccessExploring traditional uses and biological activities related to liver cancer of Saban remedy extracts for potential liver cancer treatment
Context: Saban remedy is used at Khampramong Temple to relieve adverse effects in liver cancer patients. Aims: To analyze the taste and biological activities of Saban remedy and Cassia garrettiana as a principal component species in liver cancer treatment supported in vitro and in vivo. Methods: Saban remedy and its ingredient extracts were tested for cytotoxic activity against hepatocellular carcinoma (HepG2, KKU-M156), cholangiocarcinoma cells, and normal human lung fibroblast cells (MRC-5) using the sulforhodamine B assay. Anti-inflammatory effects were evaluated through inhibition of inflammatory cytokine production (RAW 264.7 cell line), and mutagenicity and anti-mutagenicity were assessed using the Salmonella typhimurium strain TA98 and TA100 mutation assay. Both Saban remedy extracts and ethanolic C. garrettiana extract were tested in vivo for anti-hepatocarcinogenesis during the initiation stage in male Wistar rats. Results: Saban remedy, traditionally used as a purgative, exhibited bitter and bitter-nauseating flavors. The remedy demonstrated in vitro cytotoxic activity and in vivo reduction of GST-P foci in liver tissue, indicating protective and therapeutic potential against liver cancer. Saban remedy ethanolic extracts showed significant anti-inflammatory effects through nitric oxide inhibition. Notably, the aqueous extract of Saban remedy effectively reduced GST-P foci, a preneoplastic liver lesion, though it exhibited fewer biological activities compared to the ethanolic extract. This aligns with Khampramong Temple’s clinical use of the aqueous solution in cancer patients. Conclusions: The taste and biological properties of Saban remedy are correlated, supporting its use in treating liver cancer through various bioactivities.